GAD treatment and insulin secretion in recent-onset type 1 diabetes

New England Journal of Medicine

Volumn 359, Issue 18, 2008, Pages 1909-1920

  Ludvigsson, Johnny ^a   Faresjö, Maria ^a   Hjorth, Maria ^a   Axelsson, Stina ^a   Chéramy, Mikael ^a   Pihl, Mikael ^a   Vaarala, Outi ^a,j   Forsander, Gun ^b   Ivarsson, Sten ^c   Johansson, Calle ^d   Lindh, Agne ^e   Nilsson, Nils Östen ^f   Åman, Jan ^g   Örtqvist, Eva ^h   Zerhouni, Peter ⁱ   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Department of Oncology   (Sweden)

^e Section of Hematology   (Sweden)

^f HALMSTAD HOSPITAL   (Sweden)

^g ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Diamyd Medical AB   (Sweden)

^j NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; C PEPTIDE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; PLACEBO;

ADOLESCENT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENZYME THERAPY; FEMALE; HUMAN; HYPOGLYCEMIA; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 55249110198     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0804328     Document Type: Article

References (32)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-8. [Erratum, N Engl J Med 1994;330:584.]
4. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-6.
5. Ludvigsson J, Heding L, Liedén G, Marner B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983;286:176-8.
6. Dupré J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care 1988;11:Suppl 1:37-44.
7. Eisenbarth GS, Srikanta S, Jackson R, et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985;2:271-6.
8. Chase HP, Butler-Simon N, Garg S, McDuffie M, Hoops SL, O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990;33:444-6.
9. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995;38:848-52.
10. Coutant R, Landais P, Rosilio M, et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia 1998;41:1040-6.
11. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev 2001;17:131-6.
12. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001;85:149-54.
13. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, doubleblind, phase II trial. Lancet 2001;358:1749-53.
14. Lazar L, Ofan R, Weintrob N, et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 2007;23:286-91.
15. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54:1763-9.
16. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608.
17. Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum Vaccin 2005;1:143-50.
18. Jasinski JM, Eisenbarth GS. Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 2005;12:181-6.
19. Baekkeskov S, Nielsen JH, Marner H, Bilde T, Ludvigsson J, Lernmark A. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 1982;298:167-9.
20. Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol 2005;26:608-12.
21. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996;2:1348-53.
22. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998;47:894-9.
23. Agardh CD, Cilio CM, Lethagen A, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46.
24. Greenbaum CJ, Mandrup-Poulsen T, Battelino T, et al. The mixed meal tolerance test versus the glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008 July 15 (Epub ahead of print).
25. Larsson HE, Lynch K, Lernmark B, et al. Diabetes-associated HLA genotypes affect birthweight in the general population. Diabetologia 2005;48:1484-91.
26. Graham J, Hagopian WA, Kockum I, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002;51:1346-55.
27. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
28. Altman DG, Doré CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990;335:149-53.
29. Daneman D, Clarson C. Residual beta-cell function in children with type 1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987;10:484-7.
30. Steele C, Hagopian WA, Gitelman S, et al. Insulin secretion in type 1 diabetes. Diabetes 2004;53:426-33.
31. Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000;278:E759-E768.
32. White NH, Cleary PA, Dahms S, et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001;139:804-12.